Back

The ARAMIS trial - Allopurinol in patients with Refractory Angina to iMprove Ischemic Symptoms

1 September 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Inflammation in chronic coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Renato Azevedo

Hospital Sao Domingos, Sao Luis (Brazil)

6 More presentations in this session

Presentation thumbnail
Influenza vaccination and risk of cardiovascular events: a prespecified instrumental variable analysis of NUDGE-FLU-CHRONIC
Doctor D. Modin (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Assessing the cardiovascular toll of chronic inflammatory arthropathies: a case-control study on coronary artery disease severity
Mr A. Castrillo Capilla (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Awareness and perceptions on the role of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: a national study among cardiologists and nephrologists in China
Associate Professor X. Liu (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Impact of nutritional status on MACCE in CAD patients: the mediating role of inflammation
Doctor Q. Sun (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Long-term impact of residual inflammatory risk in acute myocardial infarction patients with low LDL Cholesterol levels
Professor C. Kim (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Inflammation in chronic coronary syndromes

The Event

Event poster

ESC Congress 2025

1 September 2025 14:15 CET
You may be interested in
thumbnail
Congress Presentation
A randomized, double-blind, placebo-controlled, mechanistic trial on the safety, tolerability and pharmacodynamics of ninerafaxstat in patients with angina and chronic coronary syndrome
thumbnail
Congress Presentation
Verinurad plus allopurinol for heart failure with preserved ejection fraction: results from the AMETHYST randomized controlled trial
thumbnail
Congress Session
Late-Breaking Clinical Trials: cardiovascular risk and prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources